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Summary The variability of P-glycoprotein expression in individuals is linked to a
C3435T polymorphism of the multidrug-resistance 1 (MDR1) gene, and the CC geno-
type at the C3435T polymorphism was reported to be associated with multidrug
resistance in epilepsy patients. Since population frequencies of polymorphic genes
depend on ethnic specificity, we investigated functional significance of the C3435T
polymorphism of the MDR1 gene in Korean epilepsy patients. One hundred and eight
patients with drug-responsive epilepsy, 63 patients with drug-resistant epilepsy, and
219 control migraine subjects were studied, but the analysis for C3435Tallele showed
no significant association between the CC genotype and the multidrug-resistant
epilepsy. We suggest that influence of the C3435T polymorphism in the multidrug-
resistant epilepsy may not be significant in Korean populations and further investiga-
tions in various ethnic populations would be necessary to clarify the effect of C3435T
polymorphism on the mutidrug resistance in epilepsy patients.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Resistance to antiepileptic drugs (AEDs) affects
approximately 30% of patients with epilepsy. In
addition to potential causes of apparent resistance
such as poor drug compliance or suboptimal dosing,
several clinical features like early seizure onset,
length of seizure history before treatment, or sev-
eral pathologic characteristics such as hippocampal* Correspondence to: Department of Neurology, Seoul National
University Hospital, 28 Yongkeun dong, Chongno Ku, Seoul 110-
744, Korea. Tel.: +82 2 20722923; fax: +82 2 36727553.
E-mail address: sangunlee@dreamwiz.com (S.K. Lee).
1059-1311/$ — see front matter # 2006 British Epilepsy Association
doi:10.1016/j.seizure.2006.02.015sclerosis and severe brain injury have been asso-
ciated with a high rate of drug resistance.1
Progress in epilepsy research has shown that
genetic variations can affect responsiveness to AEDs.
The multidrug-resistance 1 (MDR1) gene product P-
glycoprotein is of particular interest, and was first
identified in cancer cells as a protein responsible for
resistance to many drugs.2 P-glycoprotein is
expressed in normal tissues, where it performs a
defensive role against potentially toxic substances
in intestinal cells, renal proximal tubule cells, and
in the endothelial cells of the brain capillary endothe-
lium.3MDR1 is highlypolymorphic and the ‘apparently
silent’ C3435T polymorphism in exon 26 has been
correlated with the expression of P-glycoprotein.. Published by Elsevier Ltd. All rights reserved.
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Table 1 Characteristics of patients
Variable Drug-responsive
epilepsy (N = 108)
Drug-resistant
epilepsy (N = 63)
Sex
Male 66 31
Female 42 32
Age (year)
Mean  S.D. 32.9  9.6 34.1  9.0
Range 17—56 18—64People homozygous for the C allele have on average
substantially higher P-glycoprotein expressions than
those homozygous for the T allele.4 With regards to
epilepsy treatment, P-glycoprotein can transport
many AEDs of different action mechanisms,5 and
the increased expression of P-glycoprotein was found
in the brain specimens of those with intractable
epilepsy.6,7 Recently, it has been documented that
patients with drug-resistant epilepsy are more likely
to have the CC genotype at the C3435T polymorphism
than those with drug-responsive epilepsy,8 and sev-
eral conflicting reports9—11 have been published
regarding confirmation of the previous report.
Population frequencies ofmanypolymorphic genes
of pharmacogenetic interest depend on ethnic spe-
cificity. Association of these genes with inter-indivi-
dual differences in drug effectiveness and drug
toxicitymayalsodependon theethnic characteristics
of a population.12 Since theC3435Tpolymorphismhas
been detected in various ethnic populations with
considerable ethnic variation in frequency,13 we stu-
died the allele frequencies of the C3435T polymorph-
ism with drug-responsive or drug-resistant epilepsy.Methods
Subjects
Patients were consecutively recruited through the
epilepsy clinic at Seoul National University Hospital.
Drug-resistant or drug-responsive epilepsy were
determined according to the following criteria. Drug
resistance was defined as the occurrence of at least
four seizures over the year before recruitment with
trials of more than three antiepileptic medications
at maximal tolerated doses, which were established
by the occurrence of clinical side effects at supra-
maximal doses.
Drug responsiveness was defined as complete
seizure freedom for at least an year, up to the date
of the last follow-up visit. Control subjects were
individuals with migraine without a history of epi-
lepsy. All epilepsy and control patients were ethni-
cally homogeneous Koreans. We analyzed 108
patients with drug-responsive epilepsy, 63 patients
with drug-resistant epilepsy, and 219 control
patients. The demographic characteristics of sub-
jects are listed in Table 1.
Identification of MDR1 polymorphisms
Blood samples (5 ml) were collected in EDTA vacu-
tainer tubes for DNA extraction and MDR1 genotyp-
ing. Purified genomic DNA was extracted fromperipheral blood leukocytes using the phenol—
chloroform extraction method. Genotyping was con-
ductedusing anABI 7700 sequenceDetection System,
or ‘‘Taqman’’TM assay (Applied Biosystems). Polymer-
ase chain reaction (PCR) primers and probes were
designed using Primer ExpressTM software (Applied
Biosystems). Assay design and conditions were based
on the allelic discrimination protocol supplied by
Applied Biosystems. The cDNA 3435C allele probe
was labeled on the 50 end with the FAM receptor
dye and contained the following nucleotide sequence
50-CAAGATCCATCCCGACC-30. The cDNA 3435T allele
probewas labeled on the 50 endwith the VIC receptor
dye and contained the following nucleotide sequence
50-CAAGATCCATTCCGACC-30. Forward and reverse
primers were used to amplify the region surrounding
the C3435T polymorphism. The nucleotide sequence
of the forward primer was 50-TCTTCTTTGCTCCT-
CCATTGC-30 and of the reverse primer was 50-
TGAGCTGCGGTTTCTCTTCA-30. PCR reactions were
performed in a reaction volume 15.0 ml using the
hot-start format. The reaction components were as
follows: 2X TaqmanUniversal PCR Master Mix, 600 nM
of each primer, 100 nM of each probe, and 20 ng of
genomic DNA. PCRs were run on a Perkin Elmer
GenAmp1 9700 thermocycler using the 9600 mode
under the following conditions: 50 8C for 2 min
(AmpErase1 UNG activation), 95 8C for 10 min
(AmpliTaq Gold Activation), followed by 50 cycles
of 92 8C for 15 s (denaturation) and 60 8C for 1 min
(annealing/extension). Samples that could not be
scored were repeated. Unreadable results on the
second run were scored as undetermined (n = 17:
11 cases, 6 controls). We repeated the ‘‘Taqman’’TM
assay on 10% of the samples.Results
Demographic characteristics showed that themale to
female sex ratio in the drug-responsive group was
higher than in thedrug-resistantgroup,but this result
failed to achieve statistical significance (p = 0.130 by
x2 test). There was no age difference between the
drug-responsive and drug-resistant groups.
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Table 2 Genotype and allele distribution of the C3435T polymorphism of the ABCB1 gene in epilepsy and control
subjects
Genotypes/
alleles
Drug-responsive
epilepsy (N = 101)
Drug-resistant
epilepsy (N = 59)
p value Migraine
patients (N = 213)
Genotypes
CC 48 (47.5) 19 (32.2) 0.09 * 88 (41.5)
CT 30 (29.7) 27 (45.8) 92 (43.4)
TT 23 (22.8) 13 (30.1) 32 (15.1)
Alleles
C allele 126 (62.4) 65 (55.1) 0.20 268 (63.2)
T allele 76 (37.6) 53 (44.9) 156 (36.8)
Values expressed as N (%); comparing only CC vs. TT genotypes* in 2  2 table, p = 0.42.In patients with drug-responsive epilepsy
(N = 101), genotypic frequencies were 47.5% CC,
29.7% CT, and 22.8% TT. In patients with drug-resis-
tant epilepsy (N = 59), 32.2% CC, 45.8% CT, and 30.1%
TT. In control subjects withmigraine (N = 213), 41.5%
CC, 43.4% CT, and 15.1% TT. There was no significant
difference in genotype or allele frequencies between
groups (p > 0.05, by x2 test, Table 2).
Discussion
The mechanisms of drug resistance in epilepsy have
not been established. Hippocampal sclerosis is fre-
quently related to drug resistance in patients with
mesial temporal epilepsy. However, whether hippo-
campal sclerosis is the cause or the consequence of
chronic epileptic seizures and drug resistance is
unknown. Channelopathy has been considered,
but has been found in only a limited number of
cases with a strong familial tendency. Many patients
resistant to AED treatment are resistant to a broad
range of AEDs with different actions, and resistance
occurs across a wide variety of epilepsy types. The
functional characteristics of non-specific drug trans-
porter proteins could explain broader resistance
across types of epilepsy and to a range of AEDs.14
Polymorphisms of MDR1 gene alter in vivo transport
activity for various drugs, and a C3435T polymorph-
ism has been most frequently reported to be asso-
ciated with alterations in disposition kinetics of
various clinically useful drugs.15
However, in our study, no significant association
was found between the C3435T polymorphism and
response to AED treatment. The reason for the
contradictory results to the initial report8 is
unclear. The small sample size in the present study
may be responsible for the negative result. In
genetic association studies, initial positive studies
tend to overestimate effect size and subsequent
replication attempts require larger sample size.16
It is also possible that the inconsistent reportsresult from the ethnic difference in linkage dis-
equilibrium. There may be inter-population differ-
ence in the degree of linkage disequilibrium
between the C3435T polymorphism and disease
alleles, and studies in different ethnic groups
may cause different associations. Nevertheless,
our study may be a true negative result and show
that the influence of C3435T polymorphism in
multidrug resistance is not significant in Korean
populations, because the drug resistance in epi-
lepsy is dependent of the effects of many biologic
and genetic risk factors, and the functional impli-
cation of one factor for drug resistance might be
variable in different populations. It may be related
with the fact that there are controversies in the
effects of the C3435T polymorphism on the expres-
sion of P-glycoprotein,17 and it is still not clear
whether some important AEDs such as carbamaze-
pine and valproate are really substrates of P-gly-
coproprotein.5,18
In conclusion, we could not confirm a previously
reported association between the C3435T poly-
morphism and the multidrug-resistant epilepsy in
Korean population. Ethnic difference or small sam-
ple size may be responsible for our negative result,
but it is also possible that the original report was a
false positive finding. To clarify the exact clinical
implication of the C3435T polymorphism on the
multidrug resistance in epilepsy, further investiga-
tions in various ethnic populations would be neces-
sary. Additionally, there are other MDR1 genetic
variations that were reported to be associated with
the increased risk for multidrug resistance in epi-
lepsy,9,19 and further replication study in other
ethnic groups would also be needed.
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